WO2024089159A1 - Inhibiteurs de protéase principale - Google Patents
Inhibiteurs de protéase principale Download PDFInfo
- Publication number
- WO2024089159A1 WO2024089159A1 PCT/EP2023/079898 EP2023079898W WO2024089159A1 WO 2024089159 A1 WO2024089159 A1 WO 2024089159A1 EP 2023079898 W EP2023079898 W EP 2023079898W WO 2024089159 A1 WO2024089159 A1 WO 2024089159A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- alkyl
- independently selected
- compound
- alkoxy
- Prior art date
Links
- 229940125673 3C-like protease inhibitor Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 183
- 238000000034 method Methods 0.000 claims abstract description 40
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 12
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 10
- 230000010076 replication Effects 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 5
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 62
- 125000000217 alkyl group Chemical group 0.000 claims description 51
- 239000001257 hydrogen Substances 0.000 claims description 50
- 150000003839 salts Chemical class 0.000 claims description 49
- 239000012453 solvate Substances 0.000 claims description 43
- 125000005843 halogen group Chemical group 0.000 claims description 41
- -1 hydroxy, oxo, phenyl Chemical group 0.000 claims description 41
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 39
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 37
- 125000003545 alkoxy group Chemical group 0.000 claims description 35
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 32
- 101800000535 3C-like proteinase Proteins 0.000 claims description 28
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 claims description 28
- 241000700605 Viruses Species 0.000 claims description 27
- 150000002431 hydrogen Chemical group 0.000 claims description 27
- 201000010099 disease Diseases 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 208000015181 infectious disease Diseases 0.000 claims description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 21
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 241000711573 Coronaviridae Species 0.000 claims description 19
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 19
- 125000004043 oxo group Chemical group O=* 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 9
- 208000036142 Viral infection Diseases 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 9
- 239000001301 oxygen Substances 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 230000009385 viral infection Effects 0.000 claims description 9
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 8
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 8
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims description 7
- 241000315672 SARS coronavirus Species 0.000 claims description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 7
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 6
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 6
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 5
- 150000004677 hydrates Chemical class 0.000 claims description 5
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 4
- 241001109669 Human coronavirus HKU1 Species 0.000 claims description 4
- 241000482741 Human coronavirus NL63 Species 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 150000007942 carboxylates Chemical group 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 241000494545 Cordyline virus 2 Species 0.000 claims description 2
- 241001428935 Human coronavirus OC43 Species 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 241001678559 COVID-19 virus Species 0.000 abstract description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 238000004809 thin layer chromatography Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 150000001345 alkine derivatives Chemical class 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- SQHSJJGGWYIFCD-UHFFFAOYSA-N (e)-1-diazonio-1-dimethoxyphosphorylprop-1-en-2-olate Chemical compound COP(=O)(OC)C(\[N+]#N)=C(\C)[O-] SQHSJJGGWYIFCD-UHFFFAOYSA-N 0.000 description 4
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 4
- 241000711467 Human coronavirus 229E Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- BSPJDKCMFIPBAW-JPBGFCRCSA-M sodium;(2s)-1-hydroxy-2-[[(2s)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonate Chemical compound [Na+].N([C@@H](CC(C)C)C(=O)N[C@@H](CC1C(NCC1)=O)C(O)S([O-])(=O)=O)C(=O)OCC1=CC=CC=C1 BSPJDKCMFIPBAW-JPBGFCRCSA-M 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 244000309467 Human Coronavirus Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940125674 nirmatrelvir Drugs 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- LRFZIPCTFBPFLX-SSDOTTSWSA-N (2s)-3,3-dimethyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)C(C)(C)C LRFZIPCTFBPFLX-SSDOTTSWSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
- CVKMFSAVYPAZTQ-UHFFFAOYSA-N 2-methylhexanoic acid Chemical compound CCCCC(C)C(O)=O CVKMFSAVYPAZTQ-UHFFFAOYSA-N 0.000 description 2
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 2
- TZCYLJGNWDVJRA-UHFFFAOYSA-N 6-chloro-1-hydroxybenzotriazole Chemical compound C1=C(Cl)C=C2N(O)N=NC2=C1 TZCYLJGNWDVJRA-UHFFFAOYSA-N 0.000 description 2
- 241000004176 Alphacoronavirus Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- HTQMBOWAEPNWLI-IUCAKERBSA-N methyl (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-[(3s)-2-oxopyrrolidin-3-yl]propanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(=O)OC)C[C@@H]1CCNC1=O HTQMBOWAEPNWLI-IUCAKERBSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000012286 potassium permanganate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- YNARXVRVIBFIGZ-NKWVEPMBSA-N (3S)-3-[(2S)-2-aminobut-3-ynyl]pyrrolidin-2-one Chemical compound C#C[C@H](C[C@H](CCN1)C1=O)N YNARXVRVIBFIGZ-NKWVEPMBSA-N 0.000 description 1
- HYGSWYDPWGFRRL-GJMKMWHRSA-N (3S,3aS,6aR)-2-(4,7-dichloro-1H-indole-2-carbonyl)-N-[(2S)-1-[(3S)-2-oxopyrrolidin-3-yl]but-3-yn-2-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide Chemical compound C#C[C@H](C[C@H](CCN1)C1=O)NC([C@H]([C@@H](CCC1)[C@@H]1C1)N1C(C(NC1=C(C=C2)Cl)=CC1=C2Cl)=O)=O HYGSWYDPWGFRRL-GJMKMWHRSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 108010091324 3C proteases Proteins 0.000 description 1
- 101800000504 3C-like protease Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000008904 Betacoronavirus Species 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 241001292005 Nidovirales Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101800001016 Picornain 3C-like protease Proteins 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 101800000596 Probable picornain 3C-like protease Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108700022715 Viral Proteases Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 238000000633 chiral stationary phase gas chromatography Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- FKVUDBWXNAFSPB-MKXDVQRUSA-N methyl (1r,2s,5s)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxylate;hydrochloride Chemical compound Cl.COC(=O)[C@H]1NC[C@@H]2C(C)(C)[C@H]12 FKVUDBWXNAFSPB-MKXDVQRUSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000004784 molecular pathogenesis Effects 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Definitions
- the invention relates to compounds, pharmaceutical compositions and methods capable of inhibiting or preventing replication of a virus expressing Main Protease (M pro ).
- the invention also relates to the use of these compounds and pharmaceutical compositions in the treatment or prevention of a disease or condition caused by infection with a virus expressing Main Protease (M pro ).
- the invention further relates to the use of these compounds and pharmaceutical compositions in the manufacture of a medicament for treating infection by a virus expressing Main Protease (M pro ) and/or treating or preventing a disease or condition caused by infection by a virus expressing Main Protease (M pro ), in a subject in need thereof.
- Coronaviruses belong to the Nidovirales order of enveloped positivesense single-stranded RNA viruses (Anirudhan et al. J Med Virol. 2021 , 93, 2722).
- HCoV-229E and HCoV- OC43, with infections exhibiting symptoms similar to those of the common cold caused by rhinovirus.
- These two coronaviruses were identified in 1965 and have been extensively studied for the following 20 years.
- HCoVs human CoVs
- HCoV-229E HCoV-OC43
- HCoV-NL63 HCoV-HKU1
- MERS- CoV SARS-CoV
- SARS-CoV SARS-CoV
- SARS-CoV-2 belonging to alpha- and beta-coronaviruses about 30% of mild upper respiratory diseases are caused by HCoV-229E, HCoV- OC43, HCoV-NL63, and HCoV-HKU1.
- SARS-CoV and MERS-CoV which first appeared in China in 2002 and in Saudi Arabia in 2012, respectively, caused severe health and economic crisis at the global level. Even though its infection rate is slow, MERS-CoV infections are still ongoing.
- SARS-CoV-2 coronavirus
- COVID-19 coronavirus disease 2019
- SARS-CoV-2 is a close cousin of SARS-CoV, sharing an overall amino-acid sequence identity of 82%. Based on this similarity it is reasonable to assume that knowledge of the molecular pathogenesis of SARS-CoV and SARS-CoV-2 could result in treatment strategies for coronavirus diseases.
- Coronavirus replication and transcription function is encoded by the so-called “replicase” gene (Ziebuhr et al., J. Gen. Virol. 2000, 81 , 853), which consists of two overlapping polyproteins that are extensively processed by viral proteases.
- the C- proximal region is processed at eleven conserved interdomain junctions by the coronavirus “3C-like” or main protease (M Pro ).
- M Pro main protease
- the name “3C-like” protease derives from certain similarities between the coronavirus enzyme and the well-known picornavirus 3C proteases.
- MP ro is a 33.8-kDa cysteine protease which mediates the maturation of functional polypeptides involved in the assembly of replicationtranscription machinery.
- SARS-CoV-2 M Pro digests the polyprotein at no less than 11 conserved sites, starting with the autolytic cleavage of this enzyme itself.
- the structure of SARS- CoV-2 M Pro was established using high resolution X-ray (Zhang et al. Science. 2020, 368, 409). This study revealed that the SARS-CoV M Pro and SARS-CoV-2 M Pro have a high degree of similarity and identified a couple of differences between both SARS- CoV M Pro and SARS-CoV-2 M Pro .
- M Pro since M Pro has no human homolog and is highly conserved among all coronaviruses (Yang et al. Curr. Pharm. Des. 2006, 12, 4573), it represents an attractive drug target against coronaviruses.
- the present invention provides a compound of formula I or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, wherein:
- Z is either a oxygen or a sulphur atom
- R 1 is selected from the group consisting of hydrogen, methyl optionally substituted with one to three halo, phenyl optionally substituted with one to five halo.
- R 2 is selected from the group consisting of: wherein each R 2a is independently selected from the group consisting of hydrogen and Ci-C 6 alkyl; wherein each R 2b is independently selected from the group consisting of hydrogen, halo, hydroxy, trifluoromethyl, Ci-Ce alkyl-C(O)-, Ci-Ce alkyl-OC(O)- and Ci-Ce alkoxy Wherein each R 2c is independently selected from the group consisting of hydrogen, halo, hydroxy, oxo, trifluoromethyl, Ci-Ce alkyl ; Ci-Ce alkoxy wherein n, a, b and c are at each occurrence independently selected from 0, 1 and 2; wherein q is at each occurrence independently selected from 0, 1 , 2, 3 and 4; wherein p is at each occurrence independently selected from 0, 1 , 2 and 3; wherein m is at each occurrence independently selected from 0 to 5;
- R 3 is selected from the group consisting of hydrogen and methyl
- R 4 is selected from the group consisting of Ci-Cs alkyl, C3-C12 cycloalkyl, 4- to 12- membered heterocycloalkyl, C6-C10 aryl and 5- to 10-membered heteroaryl; wherein each R4 group is optionally substituted with one to two R 4a ; or R 3 and R 4 , taken together with the nitrogen and carbon atoms to which they are attached, form a 4- to 12-membered heterocycloalkyl or a 5- to 10-membered heteroaryl, which can be optionally substituted with one to two R 4a ;
- R 4a is at each occurrence independently selected from the group consisting of R 4b , R 4b -O-, R 4b -NH-, (R 4b ) 2 -N-, R 4b -C(O)NH- and R 4b -OC(O)NH-;
- each R 4b is at each occurrence independently selected from the group consisting of Ci-Cs alkyl, C3-C12 cycloalkyl, 4- to 12-membered heterocycloalkyl, Ce- C10 aryl and 5- to 10-membered heteroaryl; wherein each R 4b group is optionally substituted with one to two R 4c ;
- R 4c is at each occurrence independently selected from the group consisting of R 4d , R 4d -O-, R 4d -NH-, (R 4d ) 2 -N-, R 4d -C(O)NH- and R 4d -OC(O)NH-;
- each R 4d is at each occurrence is independently selected from the group consisting of Ci-Cs alkyl, C3-C12 cycloalkyl, 4- to 12-membered heterocycloalkyl, Ce- C10 aryl and 5- to 10-membered heteroaryl; wherein each R 4 , R 4b and R 4d is optionally substituted with one to five substituents at each occurrence independently selected from the group consisting of methyl, halo, hydroxy, oxo, imino and sulfanylidene.
- compounds of the invention are potent inhibitors of SARS-CoV2 and MERS-CoV.
- the alkyne group of the compounds according to the invention covalently interacts with the catalytic cysteine residue of M Pro thereby preventing viral replication.
- the inventors believe that this is a proximity-driven activity-based reaction and that the present compounds are non-reactive against other thiols. This is indicative of reduced off- target effects, compared to the M Pro known from the prior art discussed herein elsewhere.
- Z is either an oxygen or a sulphur atom
- X is either a nitrogen or a carbon atom
- Y is hydrogen or, when X is a nitrogen atom, Y and R 5 or R 6 , taken together with the nitrogen and carbon atoms to which they are attached, form a 4- to 12-membered heterocycloalkyl or a 5- to 10-membered heteroaryl;
- R 5 is selected from the group consisting of Ci-Ce alkyl, (C3-C6 cycloalkyl)-Ci-C3 alkyl and (phenyl)-Ci-C3 alkyl; wherein each R 5 group is optionally substituted with one to five substituents at each occurrence independently selected from the group consisting of C1-C3 alkyl, halo, - CF 3 ;
- R 6 is selected from the group consisting of Ci-Cs alkyl, Ci-Cs alkoxy, (Ci-Cs alkoxy)- Ci-Cs alkyl, C3-C12 cycloalkyl, (C3-C12 cycloalkyl)-Ci-C8 alkyl, (C3-C12 cycloalkyl)-Ci- Cs alkoxy, C3-C12 cycloalkoxy, (C3-C12 cycloalkoxy)-Ci-C8 alkyl, (C3-C12 cycloalkoxy)- Ci-Cs alkoxy, 4- to 12-membered heterocycloalkyl, (4- to 12-membered heterocycloalkyl)-Ci-C8 alkyl, (4- to 12-membered heterocycloalkyl)-Ci-C8 alkoxy, 4- to 12-membered heterocycloalkoxy, (4- to 12-membered heterocycloalkoxy)-Ci-C8
- R 6a at each occurrence is independently selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halo, hydroxy, oxo, phenyl, benzyl, Ci-Ce alkyl-C(O)NH-, Ci-Ce cycloalkyl-C(O)NH-, 5- to 6-membered heterocycloalkyl-C(O)NH, phenyl-C(O)NH- 5- to 6-membered heteroaryl-C(O)NH-, Ci-Ce alkyl-OC(O)NH-; wherein each R 6a group is optionally substituted with one to five fluoro or one substituent selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, chloro, hydroxy, oxo, trifluoromethyl.
- a compound as defined herein is provided, selected from the group consisting of and pharmaceutically acceptable salts, solvates and hydrates thereof
- the invention provides a method for preparing a compound as defined herein, or a pharmaceutically acceptable salt thereof, said method comprising the steps of: a) providing a first compound according to formula (X) wherein R 1 is selected from the group consisting of hydrogen, methyl optionally substituted with one to three halo, phenyl optionally substituted with one to five halo. R 2 is selected from the group consisting of:
- each R 2a is independently selected from the group consisting of hydrogen and Ci-Ce alkyl; wherein each R 2b is independently selected from the group consisting of hydrogen, halo, hydroxy, trifluoromethyl, Ci-Ce alkyl-C(O)-, Ci-Ce alkyl-OC(O)- and Ci-Ce alkoxy Wherein each R 2c is independently selected from the group consisting of hydrogen, halo, hydroxy, oxo, trifluoromethyl, Ci-Ce alkyl ; Ci-Ce alkoxy wherein n, a, b and c are at each occurrence independently selected from 0, 1 and 2; wherein q is at each occurrence independently selected from 0, 1 , 2, 3 and 4; wherein p is at each occurrence independently selected from 0, 1 , 2 and 3; wherein m is at each occurrence independently selected from 0 to 5;
- R 3 is selected from the group consisting of hydrogen and methyl; b) providing a second compound according to formula (Y) wherein Z is either an oxygen or a sulphur atom;
- R 7 is selected from the group consisting of hydroxy, halo and carboxylate
- R 4 is selected from the group consisting of Ci-Cs alkyl, C3-C12 cycloalkyl, 4- to 12- membered heterocycloalkyl, C6-C10 aryl and 5- to 10-membered heteroaryl; wherein each R4 group is optionally substituted with one to two R 4a ; or R 3 and R 4 , taken together with the nitrogen and carbon atoms to which they are attached, form a 4- to 12-membered heterocycloalkyl or a 5- to 10-membered heteroaryl, which can be optionally substituted with one to two R 4a ;
- R 4a is at each occurrence independently selected from the group consisting of R 4b , R 4b -O-, R 4b -NH-, (R 4b ) 2 -N-, R 4b -C(O)NH- and R 4b -OC(O)NH-;
- each R 4b is at each occurrence independently selected from the group consisting of Ci-Cs alkyl, C3-C12 cycloalkyl, 4- to 12-membered heterocycloalkyl, Ce- C10 aryl and 5- to 10-membered heteroaryl; wherein each R 4b group is optionally substituted with one to two R 4c ;
- R 4c is at each occurrence independently selected from the group consisting of R 4d , R 4d -O-, R 4d -NH-, (R 4d ) 2 -N-, R 4d -C(O)NH- and R 4d -OC(O)NH-;
- each R 4d is at each occurrence is independently selected from the group consisting of Ci-Cs alkyl, C3-C12 cycloalkyl, 4- to 12-membered heterocycloalkyl, Ce- C10 aryl and 5- to 10-membered heteroaryl; wherein each R 4 , R 4b and R 4d is optionally substituted with one to five substituents at each occurrence independently selected from the group consisting of methyl, halo, hydroxy, oxo, imino and sulfanylidene. c) reacting said first compound with said second compound under conditions that result in the formation of a compound of any one of the embodiments of the first aspect.
- a third aspect of the present invention provides pharmaceutical compositions comprising a compound as defined herein or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
- said pharmaceutical composition is provided in a unit dosage form suitable for oral administration, preferably in the form of a tablet or capsule.
- a fourth aspect of the present invention provides a method for treating a viral infection and/or treating or preventing a disease or condition caused by infection with a virus expressing Main Protease (MP ro ), in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of a compound as defined herein.
- MP ro Main Protease
- a fifth aspect of the present invention provides a method for inhibiting or preventing replication of a virus expressing Main Protease (MP ro ), the method comprising contacting the viruses with an inhibitory amount of a compound as defined herein.
- a use is provided of a compound as defined herein in a method of treating infection by a virus expressing Main Protease (M pro ) and/or treating or preventing a disease or condition caused by infection by a virus expressing Main Protease (M pro ).
- a use is provided of a compound as defined herein, in the manufacture of a medicament for treating infection by a virus expressing Main Protease (M pro ) and/or treating or preventing a disease or condition caused by infection by a virus expressing Main Protease (M pro ).
- the first aspect of the invention concerns a compound of formula I: or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, wherein:
- Z is either a oxygen or a sulphur atom
- R 1 is selected from the group consisting of hydrogen, methyl optionally substituted with one to three halo, phenyl optionally substituted with one to five halo.
- R 2 is selected from the group consisting of: wherein each R 2a is independently selected from the group consisting of hydrogen and Ci-C 6 alkyl; wherein each R 2b is independently selected from the group consisting of hydrogen, halo, hydroxy, trifluoromethyl, Ci-Ce alkyl-C(O)-, Ci-Ce alkyl-OC(O)- and Ci-Ce alkoxy Wherein each R 2c is independently selected from the group consisting of hydrogen, halo, hydroxy, oxo, trifluoromethyl, Ci-Ce alkyl ; Ci-Ce alkoxy wherein n, a, b and c are at each occurrence independently selected from 0, 1 and 2; wherein q is at each occurrence independently selected from 0, 1 , 2, 3 and 4; wherein p is at each occurrence independently selected from 0, 1 , 2 and 3; wherein m is at each occurrence independently selected from 0 to 5;
- R 3 is selected from the group consisting of hydrogen and methyl
- R 4 is selected from the group consisting of Ci-Cs alkyl, C3-C12 cycloalkyl, 4- to 12- membered heterocycloalkyl, C6-C10 aryl and 5- to 10-membered heteroaryl; wherein each R4 group is optionally substituted with one to two R 4a ; or R 3 and R 4 , taken together with the nitrogen and carbon atoms to which they are attached, form a 4- to 12-membered heterocycloalkyl or a 5- to 10-membered heteroaryl, which can be optionally substituted with one to two R 4a ;
- R 4a is at each occurrence independently selected from the group consisting of R 4b , R 4b -O-, R 4b -NH-, (R 4b ) 2 -N-, R 4b -C(O)NH- and R 4b -OC(O)NH-;
- each R 4b is at each occurrence independently selected from the group consisting of Ci-Cs alkyl, C3-C12 cycloalkyl, 4- to 12-membered heterocycloalkyl, Ce- C10 aryl and 5- to 10-membered heteroaryl; wherein each R 4b group is optionally substituted with one to two R 4c ;
- R 4c is at each occurrence independently selected from the group consisting of R 4d , R 4d -O-, R 4d -NH-, (R 4d ) 2 -N-, R 4d -C(O)NH- and R 4d -OC(O)NH-;
- each R 4d is at each occurrence is independently selected from the group consisting of Ci-Cs alkyl, C3-C12 cycloalkyl, 4- to 12-membered heterocycloalkyl, Ce- C10 aryl and 5- to 10-membered heteroaryl; wherein each R 4 , R 4b and R 4d is optionally substituted with one to five substituents at each occurrence independently selected from the group consisting of methyl, halo, hydroxy, oxo, imino and sulfanylidene.
- the compound of the invention is a compound according to formula I, with the proviso that R 4 comprises not more than one moiety selected from the group consisting of heterocycloalkyl and heteroaryl, where the term heterocycloalkyl includes mono- as well as polycyclic heterocycloalkyl and the term heteroaryl includes mono- as well as polycyclic heteroary.
- the compound of the invention is a compound according to formula I with the proviso that said compound according to formula (I) is not (1 S,3aR,6aS)-2-(4,7-dichloro-1 H-indole-2-carbonyl)-N-[(2S)-1-[(3S)- 2-oxopyrrolidin-3-yl]but-3-yn-2-yl]-hexahydro-1 H-cyclopenta[c]pyrrole-1 - carboxamide.
- the compound of the invention is a compound according to formula I with the proviso that said compound according to formula (I) is not any of the following compounds:
- the compound of the invention is a compound according to formula 1(a), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof.
- the compound of the invention is a compound according to formula 1(a), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, wherein R 2a is selected from the group comprising hydrogen.
- the compound of invention is a compound according to formula 1(b), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof. In certain embodiments, the compound of the invention is a compound according to formula 1(c), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof.
- the compound of the invention is a compound according to formula 1(c), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, wherein m is selected from 0 and 1 .
- the compound the invention is a compound according to formula l(d), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof.
- the compound of the invention is a compound according to formula I (d), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, wherein q is 1 .
- the compound of the invention is a compound according to formula 1(e), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof.
- the compound of the invention is a compound according to formula 1(e), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, wherein R 2b is hydrogen, b is 0, c is 1 and p is 0.
- the compound of the invention is a compound according to formula l(f), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof. 1(f)
- the compound the invention is a compound according to formula 1(f), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, wherein R 2b is hydrogen.
- the compound of the invention is a compound according to formula 1(g), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof.
- the compound of the invention is compound according to formula 1(g), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, wherein R 2b is hydrogen.
- the compound of the invention is a compound according to formula 1(h), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof.
- the compound of the invention is a compound according to formula 1(h), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, wherein R 2b is hydrogen, a is 1 and p is 0.
- the compound of the invention is a compound of any one of formulae I and 1(a) to 1(h), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, wherein R 4 is: wherein:
- Z is at each occurrence independently selected from either an oxygen or a sulphur atom
- X is either a nitrogen or a carbon atom
- Y is hydrogen or, when X is a nitrogen atom, Y and R 5 or R 6 , taken together with the nitrogen and carbon atoms to which they are attached, form a 4- to 12-membered heterocycloalkyl or a 5- to 10-membered heteroaryl; preferably a 4- to 7-membered or 9-12 membered heterocycloalkyl or a 5- to 10-membered heteroaryl;
- R 5 is selected from the group consisting of Ci-Ce alkyl, (C3-C6 cycloalkyl)-Ci-C3 alkyl and (phenyl)-Ci-C3 alkyl; wherein each R 5 group is optionally substituted with one to five substituents at each occurrence independently selected from the group consisting of C1-C3 alkyl, halo, - CF 3 ;
- R 6 is selected from the group consisting of Ci-Cs alkyl, Ci-Cs alkoxy, (Ci-Cs alkoxy)- Ci-Cs alkyl, C3-C12 cycloalkyl, (C3-C12 cycloalkyl)-Ci-C8 alkyl, (C3-C12 cycloalkyl)-Ci- Cs alkoxy, C3-C12 cycloalkoxy, (C3-C12 cycloalkoxy)-Ci-C8 alkyl, (C3-C12 cycloalkoxy)- Ci-Cs alkoxy, 4- to 12-membered heterocycloalkyl, (4- to 12-membered heterocycloalkyl)-Ci-C8 alkyl, (4- to 12-membered heterocycloalkyl)-Ci-C8 alkoxy, 4- to 12-membered heterocycloalkoxy, (4- to 12-membered heterocycloalkoxy)-Ci-C8
- R 6a at each occurrence is independently selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, halo, hydroxy, oxo, phenyl, benzyl, Ci-Ce alkyl-C(O)NH-, Ci-Ce cycloalkyl-C(O)NH-, 5- to 6-membered heterocycloalkyl-C(O)NH, phenyl-C(O)NH-, 5- to 6-membered heteroaryl-C(O)NH-, Ci-Ce alkyl-OC(O)NH-, preferably selected from the group consisting of C1-C3 alkyl, C1-C3 alkoxy, fluoro, hydroxy, oxo, phenyl, benzyl, C1-C6 alkyl-C(O)NH- Ci-Ce cycloalkyl-C(O)NH- 5- to 6-membered heterocycloalkyl- C(O)NH, phen
- the compound of the invention is a compound according to general formula (II), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof.
- the compound of the invention is a compound according to formula 11(a), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof.
- the compound of the invention is a compound according to formula 11(a), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, wherein R 2a is selected from the group comprising hydrogen.
- the compound of the invention is a compound according to formula 11(b), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof.
- the compound of the invention is a compound according to formula 11(c), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof.
- the compound of the invention is a compound according to formula 11(c), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, wherein m is selected from 0 and 1 .
- the compound of the invention is a compound according to formula 11(d), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof.
- the compound of the invention is a compound according to formula 11(d), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, wherein q is 1 .
- the compound of the invention is a compound according to formula ll(e), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof.
- the compound of the invention is a compound according to formula ll(e), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, wherein R 2b is hydrogen, b is 0, c is 1 and p is 0.
- the compound of the invention is a compound according to formula ll(f), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof.
- the compound of the invention is a compound according to formula 11(f), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, wherein R 2b is hydrogen.
- the compound of the invention is a compound according to formula 11(g), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof. H(g)
- the compound of the invention is a compound according to formula 11(g), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, wherein R 2b is hydrogen.
- the compound of the invention is a compound according to formula 11(h), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof.
- the compound of the invention is a compound according to formula 11(h), or a pharmaceutically acceptable salt, solvate and/or hydrate thereof, wherein R 2b is hydrogen, a is 1 and p is 0.
- R 3 preferably represents hydrogen.
- R 1 preferably represents hydrogen, fluoro or trimethylfluoro, most preferably hydrogen.
- R 5 is preferably selected from the group consisting of:
- R 5 is preferably selected from the group consisting of:
- R 6 is preferably is selected from the group consisting of:
- R 6 is preferably is selected from the group consisting of: In the above formulae (II) and (lla-llh) when X is nitrogen, Y and R 6 , taken together with the nitrogen and carbon atoms to which they are attached, form
- Compounds of the invention contain at least one chiral centre and, therefore, exist as stereoisomers, such as enantiomers and diastereomers. According to the invention, the chemical structures depicted herein, and therefore the compounds of the invention, encompass all of the corresponding compound's stereoisomers.
- the chemical structures depicted herein by structural formula not indicating a specific stereochemistry encompass both a stereochemical ly pure form and mixtures of different stereoisomers, such as enantiomers and/or diastereomers.
- the invention encompasses compounds of formulae (I), (la-lh), (II) and (lla-llh), in enantiomerically pure form, enantiomerically-enriched form, diastereomerically pure form, diastereomerically enriched form, as racemic mixture or as diastereomeric mixture.
- compounds of formulae (I), (la-lh), (II) and (lla-llh), wherein one of the stereoisomers makes up more than 60 mol%, more than 80 mol%, more than 90 mol%, more than 95 mol%, more than 97 mol%, more than 98.5 mol%, more than 99 mol% of the compound.
- a compound is considered stereochemical ly pure when one of the stereoisomers makes up more than more than 90 mol%, more than 95 mol%, more than 97 mol%, more than 98.5 mol%, more than 99 mol% of the compound.
- Enantiomeric mixtures can be resolved into their component enantiomers or stereoisomers by well-known methods, such as chiral-phase gas chromatography, chiral-phase high performance liquid chromatography, or crystallizing the compound in a chiral solvent.
- Diastereomeric mixtures can be resolved into their component diastereomers by well-known methods for separating two chemical compounds, for example based on their different melting points, boiling points etc.
- Stereochemically pure compounds can also be obtained from stereochemically pure intermediates, reagents, and catalysts by well-known asymmetric synthetic methods.
- the compound of the invention has the absolute configuration as represented by formula (lx).
- the compound of the invention is compound selected from the group consisting of: and pharmaceutically acceptable salts, solvates and hydrates thereof,
- each R 3b is independently selected from the group consisting of hydrogen, halo, hydroxy, trifluoromethyl, -C(O)Ci-Ce alkyl, -C(O)OCi-Ce alkyl and Ci-Ce alkoxy; wherein a is at each occurrence independently selected from 0, 1 and 2.
- the compound of the invention is compound selected from the group consisting of: (1 R,2S,5S)-3-((S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-/ ⁇ /- ((S)-1 -((S)-2-oxopyrrolidin-3-yl)but-3-yn-2-yl)-3-azabicyclo[3.1 ,0]hexane-2- carboxamide, benzyl ((S)-4-methyl-1 -oxo-1 -(((S)-1 -((S)-2-oxopyrrolidin-3-yl)but-3-yn-2- yl)amino)pentan-2-yl)carbamate, 4-methoxy-/V-((S)-4-methyl-1 -oxo-1 -(((S)-1 -((S)-2-oxopyrrolidin-3-yl)
- IIIPAC names proposed herein for the compounds (and intermediates) of the invention were generated using Chemdraw, level: Professional, version 20.0.0.38 (PerkinElmer Informatics, Inc., Waltham, Massachusetts, United States). To the extent that the generated IUPAC names and the structures provided herein do not fully correspond, the structures are correct and leading.
- the compound of formula I is compound selected from the group consisting of and pharmaceutically acceptable salts, solvates and hydrates thereof.
- pharmaceutically acceptable as used herein has its conventional meaning and refers to compounds, material, compositions and/or dosage forms, which are, within the scope of sound medical judgment suitable for contact with the tissues of mammals, especially humans, without excessive toxicity, irritation, allergic response and other problem complications commensurate with a reasonable benefit/risk ratio.
- Suitable examples of pharmaceutically acceptable salts of the compounds of the present invention include the acid addition salts formed with inorganic acids (e.g.
- hydrochloric acid hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like
- organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, fumaric acid, maleic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalene sulfonic acid, naphthalene disulfonic acid, methane sulfonic acid, p-toluene sulfonic acid and polygalacturonic acid.
- the invention concerns a method for preparing a compound as defined herein, said method comprising the steps of: a) providing a first compound according to formula (X) wherein R 1 is selected from the group consisting of hydrogen, methyl optionally substituted with one to three halo, phenyl optionally substituted with one to five halo.
- R 2 is selected from the group consisting of: wherein each R 2a is independently selected from the group consisting of hydrogen and Ci-C 6 alkyl; wherein each R 2b is independently selected from the group consisting of hydrogen, halo, hydroxy, trifluoromethyl, Ci-Ce alkyl-C(O)-, Ci-Ce alkyl-OC(O)- and Ci-Ce alkoxy Wherein each R 2c is independently selected from the group consisting of hydrogen, halo, hydroxy, oxo, trifluoromethyl, Ci-Ce alkyl ; Ci-Ce alkoxy wherein n, a, b and c are at each occurrence independently selected from 0, 1 and 2; wherein q is at each occurrence independently selected from 0, 1 , 2, 3 and 4; wherein p is at each occurrence independently selected from 0, 1 , 2 and 3; wherein m is at each occurrence independently selected from 0 to 5;
- R 3 is selected from the group consisting of hydrogen and methyl; b) providing a second compound according to formula (Y) z
- R 7 is selected from the group consisting of hydroxy, halo and carboxylate
- R 4 is selected from the group consisting of Ci-Cs alkyl, C3-C12 cycloalkyl, 4- to 12- membered heterocycloalkyl, C6-C10 aryl and 5- to 10-membered heteroaryl; wherein each R4 group is optionally substituted with one to two R 4a ; or R 3 and R 4 , taken together with the nitrogen and carbon atoms to which they are attached, form a 4- to 12-membered heterocycloalkyl or a 5- to 10-membered heteroaryl, which can be optionally substituted with one to two R 4a ;
- R 4a is at each occurrence independently selected from the group consisting of R 4b , R 4b -O-, R 4b -NH-, (R 4b ) 2 -N-, R 4b -C(O)NH- and R 4b -OC(O)NH-;
- each R 4b is at each occurrence independently selected from the group consisting of Ci-Cs alkyl, C3-C12 cycloalkyl, 4- to 12-membered heterocycloalkyl, Ce- C10 aryl and 5- to 10-membered heteroaryl; wherein each R 4b group is optionally substituted with one to two R 4c ;
- R 4c is at each occurrence independently selected from the group consisting of R 4d , R 4d -O-, R 4d -NH-, (R 4d ) 2 -N-, R 4d -C(O)NH- and R 4d -OC(O)NH-;
- each R 4d is at each occurrence is independently selected from the group consisting of Ci-Cs alkyl, C3-C12 cycloalkyl, 4- to 12-membered heterocycloalkyl, Ce- C10 aryl and 5- to 10-membered heteroaryl; wherein each R 4 , R 4b and R 4d is optionally substituted with one to five substituents at each occurrence independently selected from the group consisting of methyl, halo, hydroxy, oxo, imino and sulfanylidene. c) reacting said first compound with said second compound under conditions that result in the formation of a compound of the invention.
- R 7 preferably represents hydroxy, iodo, bromo, chloro or fluoro, most preferably hydroxy.
- more than 60 mol%, more than 80 mol%, more than 90 mol%, more than 95 mol%, more than 97 mol%, more than 98.5 mol%, more than 99 mol% of the compound of formula (X) provided in step a) is a compound with absolute configuration as represented by formula (Xa).
- reaction is performed in a suitable solvent, such as a chloroalkane, e.g. dichloromethane.
- a suitable solvent such as a chloroalkane, e.g. dichloromethane.
- the reaction is performed at a suitable temperature, e.g. at room temperature.
- the reaction is performed in the presence of a base, preferably a sterically hindered base, more preferably a sterically hindered amine base, such as triethylamine or N,N-Diisopropylethylamine, preferably N,N- Diisopropylethylamine.
- the reaction is performed in the presence of one or more coupling reagents, such as hydroxybenzotriazole, 6-Chloro-1 - hydroxybenzotriazole, 1 -Hydroxy-7-azabenzotriazole, N,N-Diisopropylethylamine, N,N'-Dicyclohexylcarbodiimide or 1 -Ethyl-3-(3-dimethylaminopropyl)carbodiimide, (Benzotriazol-1 -yloxy)tris(dimethylamino)phosphonium hexafluorophosphate,
- one or more coupling reagents such as hydroxybenzotriazole, 6-Chloro-1 - hydroxybenzotriazole, 1 -Hydroxy-7-azabenzotriazole, N,N-Diisopropylethylamine, N,N'-Dicyclohexylcarbodiimide or 1 -Ethyl
- Bromotripyrrolidinophosphonium hexafluorophosphate Bis(2-oxo-3- oxazolidinyl)phosphinic chloride, preferably hydroxybenzotriazole and 1 -Ethyl-3-(3- dimethylaminopropyl)carbodiimide.
- the reaction is performed in the presence of one or more racemization supressing agents, such as such as hydroxybenzotriazole, 6- Chloro-1 -hydroxybenzotriazole, 1 -Hydroxy-7-azabenzotriazole, (Benzotriazol-1 - yloxy)tris(dimethylamino)phosphonium hexafluorophosphate, (Benzotriazol-1 - yloxy)tripyrrolidinophosphonium hexafluorophosphate, (7-Azabenzotriazol-1 - yloxy)tripyrrolidinophosphonium hexafluorophosphate,
- racemization supressing agents such as such as hydroxybenzotriazole, 6- Chloro-1 -hydroxybenzotriazole, 1 -Hydroxy-7-azabenzotriazole, (Benzotriazol-1 - yloxy)tris(dimethylamino)phosphonium hexafluoro
- the invention concerns pharmaceutical composition
- a pharmaceutically acceptable carrier or diluent comprising a compound of the invention and a pharmaceutically acceptable carrier or diluent.
- the pharmaceutical composition is provided in a unit dosage form suitable for oral administration, preferably in the form of a tablet or capsule.
- Another aspect of the invention concerns a method of treating infection by a virus expressing Main Protease (Mpro) and/or treating or preventing a disease or condition caused by infection by a virus expressing Main Protease (Mpro), in a subject in need thereof, the method comprising administering to said subject a therapeutically effective amount of a compound or a pharmaceutical composition of the invention.
- Another aspect of the invention concerns a method of inhibiting or preventing replication of a virus expressing Main Protease (MP ro ), the method comprising contacting the viruses with an inhibitory amount of a compound according to the invention.
- Another aspect of the invention concerns the use of a compound according to the invention, in a method of treating infection by a virus expressing Main Protease (MP ro ) and/or treating or preventing a disease or condition caused by infection by a virus expressing Main Protease (M pro ), in a subject in need thereof.
- MP ro Main Protease
- M pro Main Protease
- Another aspect of the invention concerns the use of a compound according to the invention, in the manufacture of a medicament for treating infection by a virus expressing Main Protease (MP ro ) and/or treating or preventing a disease or condition caused by infection by a virus expressing Main Protease (M pro ), in a subject in need thereof.
- MP ro Main Protease
- M pro Main Protease
- treat when used in conjunction with a specific disease or symptom (for example: “method of treating disease ...”) refers to curing, alleviating or abrogating said disease and/or accompanying symptoms, diminishing extent of disease, stabilizing (i.e. not worsening) the state of disease, delaying or slowing of disease progression, ameliorating the disease state, prolonging survival (as compared to expected survival without treatment), etc.
- prevent refers to reducing the risk for a subject to acquire a disease and/or accompanying symptoms, delaying the moment a subject acquires disease, etc.
- treat when used in relation to a patient or subject (for example: “method of treating a subject”), typically refers to the act of administering a therapeutic compound to said patient or subject for whatever therapeutic and/or prophylactic purpose.
- M Pro main protease
- M Pro Main Protease
- Alterative names for M Pro include 3C-like protease, 3CL or 3CL pro .
- the viral infection is infection with a coronavirus, preferably a coronavirus selected from the group consisting of HCoV-229E, HCoV- OC43, HCoV-NL63, HCoV-HKU1 , MERS-CoV, SARS-CoV, and SARS-CoV-2.
- a coronavirus selected from the group consisting of HCoV-229E, HCoV- OC43, HCoV-NL63, HCoV-HKU1 , MERS-CoV, SARS-CoV, and SARS-CoV-2.
- the disease or condition caused by a viral infection is a respiratory illness, such as acute respiratory distress syndrome (ARDS), Middle East respiratory syndrome (MERS) and COVID-19.
- a "therapeutically effective amount”, “effective amount” or a “sufficient amount” of a compound of the present invention is a quantity sufficient to, when administered to the subject, including a mammal, for example a human, effect beneficial or desired results, including clinical results, and, as such, an "effective amount” or synonym thereto depends upon the context in which it is being applied.
- therapeutically effective amounts of the compounds of the present invention are used to treat, modulate, attenuate, reverse, or effect viral infection in a mammal.
- An "effective amount” is intended to mean that amount of a compound that is sufficient to treat, prevent or inhibit viral infections and/or diseases associated with such viral infections.
- compositions as defined herein can exist in the form of a pharmaceutically acceptable salt or solvate.
- Such forms will typically be equally suitable for use in the present invention although, is as immediately apparent to those skilled in the art, the amount of such a salt, hydrate or solvate to be administered and/or to be incorporated into a unit dose form needs to be adjusted to take account of the molecular weight difference between the free base and salt form.
- a compartment refers to one or more than one compartment.
- Figure 1 depicts the antiviral activity against SARS-CoV-2 of UbiQ-CoV-002 compared to control compound GC376 and of UbiQ-CoV-004 compared to control compound PF-07321332.
- Figure 2 depicts the antiviral activity against MERS-CoV of UbiQ-CoV-004 compared to control compound PF-07321332.
- LC-MS measurements were performed on a Micromass LCT Premier (Waters) equipped with a 2795 separation module (Alliance HT).
- Mobile phases: A 1 % CH3CN, 0.1 % formic acid in milliQ water.
- B 1 % milliQ water and 0.1 % formic acid in CH3CN.
- GC-376 was obtained according to the method previously described by Kim et al. (J. Virol. 2012, 86, 11754). To a solution of potassium carbonate (0.3 g, 2.1 mmol) in water (5 mL) was added GC-376 (225 mg, 0.44 mmol, Ambeed A1003140, CAS nr. 1416992-39-6) and ethyl acetate (5 mL). After stirring the mixture at 20°C for 2 h, the organic phase was separated and dried with sodium sulfate. Aldehyde GC-373 was obtained as an oil after evaporation of ethyl acetate.
- Ohira-Bestmann reagent (dimethyl (1 -diazo-2-oxopropyl)phosphonate, 84 pL, 0.53 mmol) was dissolved in CH3CN (5 mL) and potassium carbonate (146 mg, 1 .06 mmol) was added. After stirring this suspension at room temperature for 10 minutes, the crude GC-373 (0.44 mmol) was dissolved in methanol (2 mL) and added to the reaction mixture. After stirring overnight, analysis by TLC and LC-MS showed complete consumption of starting material and formation of UbiQ-CoV-002 (Rf in CH2CI2/methanol 95/5: 0.5).
- reaction mixture was concentrated in vacuo at 50°C and the residue diluted with water (25 mL). After adding 1 N HCI (25 mL), a white precipitate was formed. Upon adding ethyl acetate (200 mL), the solid dissolved in the organic layer.
- Amino alkyne 5 (0.45 gr, 2.4 mmol) and building block 6 (1.04 gr, 2.88 mmol) were dissolved in 50 mL CH2CI2 followed by addition of Hydroxybenzotriazole (HOBt, 0.48 mmol, 63 mg), N,N-diispropylethylamine (DiPEA, 7.2 mmol, 1 .25 mL) and 1 -ethyl- 3-(3'-dimethylaminopropyl)carbodiimide HCI (EDC, 0.45 gr, 2.88 mmol). After stirring overnight at room temperature, TLC analysis with KMnCM staining showed complete consumption of 5.
- HABt Hydroxybenzotriazole
- DIPEA N,N-diispropylethylamine
- EDC 1 -ethyl- 3-(3'-dimethylaminopropyl)carbodiimide HCI
Abstract
L'invention concerne des composés de formule (I) dans laquelle R1, R2, R3 et R4 sont tels que définis dans la description, des compositions pharmaceutiques comprenant les composés et des procédés de synthèse de composés selon la formule I. La présente invention concerne en outre des procédés de traitement de la COVID-19 chez un patient par administration de quantités thérapeutiquement efficaces des composés et des procédés d'inhibition ou de prévention de la réplication du SARS-CoV-2 avec les composés de l'invention et des utilisations des composés de l'invention dans ces procédés et dans la fabrication d'un médicament.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22204213 | 2022-10-27 | ||
EP22204213.7 | 2022-10-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024089159A1 true WO2024089159A1 (fr) | 2024-05-02 |
Family
ID=84044807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/079898 WO2024089159A1 (fr) | 2022-10-27 | 2023-10-26 | Inhibiteurs de protéase principale |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024089159A1 (fr) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020244970A1 (fr) * | 2019-06-06 | 2020-12-10 | Basf Se | Nouveaux carboxamides de pyridine carbocycliques |
WO2021205296A1 (fr) | 2020-04-05 | 2021-10-14 | Pfizer Inc. | Méthode de traitement de la covid-19 |
WO2021207409A2 (fr) | 2020-04-08 | 2021-10-14 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Inhibiteurs à petites molécules de la replication virale du sars-cov-2 et leurs utilisations |
WO2021205298A1 (fr) | 2020-04-05 | 2021-10-14 | Pfizer Inc. | Composés et méthodes destinés au traitement de la covid-19 |
WO2021205290A1 (fr) | 2020-04-05 | 2021-10-14 | Pfizer Inc. | Composés et procédé de traitement de la covid-19 |
WO2021252491A1 (fr) * | 2020-06-10 | 2021-12-16 | Aligos Therapeutics, Inc. | Composés antiviraux pour le traitement d'infections à coronavirus, picornavirus et norovirus |
WO2021250648A1 (fr) | 2020-09-03 | 2021-12-16 | Pfizer Inc. | Composés antiviraux contenant du nitrile |
WO2022013684A1 (fr) | 2020-07-11 | 2022-01-20 | Pfizer Inc. | Dérivés d'hétéroaryl cétone antiviraux |
WO2022040186A1 (fr) | 2020-08-18 | 2022-02-24 | Anixa Biosciences, Inc. | Inhibiteurs de cystéine protéase mpro |
-
2023
- 2023-10-26 WO PCT/EP2023/079898 patent/WO2024089159A1/fr unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020244970A1 (fr) * | 2019-06-06 | 2020-12-10 | Basf Se | Nouveaux carboxamides de pyridine carbocycliques |
WO2021205296A1 (fr) | 2020-04-05 | 2021-10-14 | Pfizer Inc. | Méthode de traitement de la covid-19 |
WO2021205298A1 (fr) | 2020-04-05 | 2021-10-14 | Pfizer Inc. | Composés et méthodes destinés au traitement de la covid-19 |
WO2021205290A1 (fr) | 2020-04-05 | 2021-10-14 | Pfizer Inc. | Composés et procédé de traitement de la covid-19 |
WO2021207409A2 (fr) | 2020-04-08 | 2021-10-14 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Inhibiteurs à petites molécules de la replication virale du sars-cov-2 et leurs utilisations |
WO2021252491A1 (fr) * | 2020-06-10 | 2021-12-16 | Aligos Therapeutics, Inc. | Composés antiviraux pour le traitement d'infections à coronavirus, picornavirus et norovirus |
WO2022013684A1 (fr) | 2020-07-11 | 2022-01-20 | Pfizer Inc. | Dérivés d'hétéroaryl cétone antiviraux |
WO2022040186A1 (fr) | 2020-08-18 | 2022-02-24 | Anixa Biosciences, Inc. | Inhibiteurs de cystéine protéase mpro |
WO2021250648A1 (fr) | 2020-09-03 | 2021-12-16 | Pfizer Inc. | Composés antiviraux contenant du nitrile |
Non-Patent Citations (14)
Title |
---|
ANIRUDHAN ET AL., J MED VIROL., vol. 93, 2021, pages 2722 |
CAS , no. 148893-10-1 |
CAS, no. 1416992-39-6 |
KATRITZKY ALAN R ET AL: "A Conceptually New Approach to the Synthesis of Secondary Amides and Thioamides1", J. ORG. CHEM, vol. 53, 1 January 1988 (1988-01-01), pages 5854 - 5856, XP093040301 * |
KIM ET AL., J. VIROL., vol. 86, 2012, pages 11754 |
KIM ET AL., PLOS PATHOG, vol. 12, 2016, pages e1005531 |
KLAUBER ERIC G. ET AL: "Merging Nucleophilic and Hydrogen Bonding Catalysis: An Anion Binding Approach to the Kinetic Resolution of Propargylic Amines", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 132, no. 39, 15 September 2010 (2010-09-15), pages 13624 - 13626, XP093040298, ISSN: 0002-7863, DOI: 10.1021/ja105337h * |
KOLLETH AMANDINE ET AL: "Kinetic resolution of propargylamines via a highly enantioselective non-enzymatic N-acylation process", CHEMICAL COMMUNICATIONS, vol. 48, no. 85, 1 January 2012 (2012-01-01), UK, pages 10511, XP093040295, ISSN: 1359-7345, DOI: 10.1039/c2cc35719d * |
MARION GARREAU ET AL: "C-Terminal Bioconjugation of Peptides through Photoredox Catalyzed Decarboxylative Alkynylation", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, VERLAG CHEMIE, HOBOKEN, USA, vol. 58, no. 24, 8 May 2019 (2019-05-08), pages 8182 - 8186, XP072087686, ISSN: 1433-7851, DOI: 10.1002/ANIE.201901922 * |
OWEN ET AL., SCIENCE, vol. 374, 2021, pages 1586 |
PEDERSEN ET AL., J. FELINE MED. SURG., vol. 20, 2018, pages 378 |
YANG ET AL., CURR. PHARM. DES., vol. 12, 2006, pages 4573 |
ZHANG ET AL., SCIENCE, vol. 368, 2020, pages 409 |
ZIEBUHR ET AL., J. GEN. VIROL., vol. 81, 2000, pages 853 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11541034B2 (en) | Nitrile-containing antiviral compounds | |
US20230339930A1 (en) | Antiviral Heteroaryl Ketone Derivatives | |
CN114057702B (zh) | 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途 | |
CN115960088A (zh) | 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途 | |
JP2024511881A (ja) | SARS-COV-2 Mpro阻害剤化合物 | |
JP5128126B2 (ja) | 置換ジケトピペラジンオキシトシンアンタゴニストとしてのその使用 | |
JPH07500604A (ja) | 高血圧治療用エチルアラニンアミノジオール化合物 | |
WO2010065861A2 (fr) | Inhibiteurs de bace 1 et méthodes de traitement de la maladie d'alzheimer | |
WO2024089159A1 (fr) | Inhibiteurs de protéase principale | |
CN107619392B (zh) | 1h-吲唑-4-醚类化合物及其作为ido抑制剂的用途 | |
AU2021260048B2 (en) | Antiviral 1,3-di-oxo-indene compounds | |
RU2786722C1 (ru) | Нитрилсодержащие противовирусные соединения | |
JPH08259532A (ja) | ペプチド様化合物又はその薬理的に許容される塩 | |
WO2021214080A1 (fr) | Composés de 1,3-di-oxo-indène antiviraux | |
WO2020219808A1 (fr) | Inhibiteurs dicarbamate de ns5a pour le traitement d'infections par le virus de l'hépatite c et de maladies associées | |
NZ787942A (en) | Nitrile-containing antiviral compounds | |
JPH05148249A (ja) | ベンゾオキサジノン誘導体 | |
CN117858867A (zh) | Sars-cov-2 mpro抑制剂化合物 |